Mavacamten (CAMZYOS) First-in-Class Small-Molecule Myosin Inhibitor for Treatment of Obstructive Hypertrophic Cardiomyopathy

Author Affiliation: Nurse Scientist & Faculty, Premier Health - Miami Valley Hospital, Dayton, Ohio 1 Wyoming Street NW 4242 Dayton, OH 45409. The author reports no conflicts of interest. Correspondence: Patricia Anne O'Malley, PhD, APRN-CNS, Premier Health - Miami Valley Hospital, Dayton, OH ([email protected]).